Tarsus Pharmaceuticals, Inc. (TARS)
TARS moved a median of 0.00% 30 minutes after news, and -0.23% by the close. How TARS actually reacts to news — the realized, point-in-time move the market made, measured across 390 labeled events over the last three years with zero look-ahead.
TARS’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.01% | 47% | 389 |
| 30-min | 0.00% | 49% | 390 |
| 60-min | -0.12% | 47% | 390 |
| to close | -0.23% | 47% | 389 |
| Middle 50% of TARS reactions | -1.12% to +1.25% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 390 |
Half of all Tarsus Pharmaceuticals, Inc. news events land between -1.12% and +1.25% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How TARS reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 11 | +0.24% | 55% | +0.12% |
| Coverage initiations | 12 | +0.87% | 83% | -3.69% |
| Rating reiterations | 48 | +0.14% | 52% | -0.09% |
| Price-target raises | 19 | -0.33% | 42% | -1.72% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how TARS ranks against every other measured name →
That’s how TARS usually reacts — get an email when it moves on news →Email me when TARS moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to TARS's baseline. Nothing else.
Recent TARS events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K/A Tarsus Pharmaceuticals, For: Sep 04 | SEC filing · Form 8-K | SEC EDGAR | +0.47% | +2.44% | |
| Form S-3ASR Tarsus Pharmaceuticals, | SEC filing · Form S-3ASR | SEC EDGAR | +0.47% | +2.44% | |
| Tarsus Plans to Present 11 Abstracts Highlighting New Insights in Demodex Blepharitis, Ocular Rosacea and the Real-World Impact of XDEMVY at the American Academy of Optometry 2026 Annual Meeting | Press release | GlobeNewswire | +1.27% | +0.62% | |
| Form 8-K Tarsus Pharmaceuticals, For: Sep 04 | SEC filing · Form 8-K | SEC EDGAR | +0.89% | -3.60% | |
| Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care | Press release | GlobeNewswire | +0.37% | +9.77% | |
| Tarsus to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +1.65% | +10.89% | |
| Form 10-Q Tarsus Pharmaceuticals, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +4.09% | +13.36% | |
| Form 8-K Tarsus Pharmaceuticals, For: Aug 05 | SEC filing · Form 8-K | SEC EDGAR | +4.09% | +13.36% | |
| Form 8-K Tarsus Pharmaceuticals, For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | +4.09% | +13.36% | |
| Form 8-K Tarsus Pharmaceuticals, For: Jul 31 | SEC filing · Form 8-K | SEC EDGAR | +4.09% | +13.36% | |
| Tarsus Pharmaceuticals Announces Oversubscribed $125.0 Million Private Placement Equity Financing | Press release | GlobeNewswire | +4.09% | +13.36% | |
| Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals and Advance Eye Care Leadership Position | Press release | GlobeNewswire | +4.09% | +13.36% | |
| Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth | Press release | GlobeNewswire | +4.09% | +13.36% | |
| Tarsus to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026 | Press release | GlobeNewswire | +4.09% | +13.36% | |
| Form 8-K Tarsus Pharmaceuticals, For: Jul 13 | SEC filing · Form 8-K | SEC EDGAR | +2.15% | -2.67% | |
| Tarsus Pharmaceuticals Announces Executive Leadership Transition as Company Advances Next Phase of Growth | Press release | GlobeNewswire | +2.15% | -2.67% | |
| Form 8-K Tarsus Pharmaceuticals, For: Jul 06 | SEC filing · Form 8-K | SEC EDGAR | +1.01% | -4.33% | |
| Tarsus Advances Eye Care Leadership Strategy with Acquisition of iRenix Medical and Late-Stage Asset IRX-101 | Press release | GlobeNewswire | +1.01% | -4.33% | |
| Form 8-K Tarsus Pharmaceuticals, For: Jun 25 | SEC filing · Form 8-K | SEC EDGAR | -0.70% | +1.60% | |
| Tarsus to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | -0.47% | -0.92% | |
| Tarsus and John Cena Partner to Raise Awareness of Demodex blepharitis, a Common Eyelid Disease Affecting Approximately 25 Million Americans | Press release | GlobeNewswire | +1.09% | +0.59% | |
| Tarsus to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | -0.62% | -4.30% | |
| Form 10-Q Tarsus Pharmaceuticals, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -2.15% | +2.01% | |
| Form 8-K Tarsus Pharmaceuticals, For: May 06 | SEC filing · Form 8-K | SEC EDGAR | -2.15% | +2.01% | |
| Tarsus Reports First Quarter 2026 Financial Results and Recent Business Achievements | Press release | GlobeNewswire | -2.15% | +2.01% | |
| Tarsus to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026 | Press release | GlobeNewswire | +2.01% | +5.00% | |
| Form ARS Tarsus Pharmaceuticals, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -0.85% | -1.21% | |
| Form DEF 14A Tarsus Pharmaceuticals, For: Jun 25 | SEC filing · Form DEF | SEC EDGAR | -0.85% | -1.21% | |
| Form DEFA14A Tarsus Pharmaceuticals, | SEC filing · Form DEFA14A | SEC EDGAR | -0.85% | -1.21% | |
| Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease | Press release | GlobeNewswire | +0.30% | +3.80% | |
| TP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to Tarsus | Press release | GlobeNewswire | +0.17% | -2.94% | |
| Tarsus to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +1.47% | -0.30% | |
| Form 10-K Tarsus Pharmaceuticals, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +3.90% | +0.62% | |
| Form 8-K Tarsus Pharmaceuticals, For: Feb 23 | SEC filing · Form 8-K | SEC EDGAR | +3.90% | +0.62% | |
| Form S-8 Tarsus Pharmaceuticals, | SEC filing · Form S-8 | SEC EDGAR | +3.90% | +0.62% | |
| Tarsus Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Achievements | Press release | GlobeNewswire | +3.90% | +0.62% | |
| Form 8-K Tarsus Pharmaceuticals, For: Feb 18 | SEC filing · Form 8-K | SEC EDGAR | +1.39% | +1.07% | |
| Tarsus Pharmaceuticals Appoints Renowned Biopharmaceutical Leader and Former Allergan CEO, David Pyott, to its Board of Directors | Press release | GlobeNewswire | +1.39% | +1.07% | |
| Tarsus to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, February 23, 2026 | Press release | GlobeNewswire | +1.39% | +1.07% | |
| Form 8-K Tarsus Pharmaceuticals, For: Jan 12 | SEC filing · Form 8-K | SEC EDGAR | -0.57% | -1.90% | |
| Tarsus to Participate in Upcoming Investor Conference | Press release | GlobeNewswire | -0.39% | -4.89% | |
| Tarsus to Participate in Upcoming Investor Conference | Press release | GlobeNewswire | -0.12% | -0.96% | |
| Form 10-Q Tarsus Pharmaceuticals, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.93% | -0.44% | |
| Form 8-K Tarsus Pharmaceuticals, For: Nov 04 | SEC filing · Form 8-K | SEC EDGAR | +0.93% | -0.44% | |
| Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements | Press release | GlobeNewswire | +0.93% | -0.44% | |
| Tarsus to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025 | Press release | GlobeNewswire | +0.06% | -0.49% | |
| Tarsus to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +0.04% | -0.14% | |
| Form 10-Q Tarsus Pharmaceuticals, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +2.40% | +6.63% | |
| Form 8-K Tarsus Pharmaceuticals, For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | +2.40% | +6.63% | |
| Named 'Great Place to Work,' Moon Rabbit Reports Record Growth, New Clients, Industry Accolades | Press release | PR Web | -0.07% | +0.75% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the TARS section they belong to.
Where else TARS is measured.
TARS earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Tarsus Pharmaceuticals, Inc.'s median reaction calculated?
Every labeled TARS news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 390 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 49% of TARS's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does TARS's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.